|Articles|December 1, 2004
FDA grants Vitrase 5 years' exclusivity
The FDA has extended ISTA Pharmaceuticals' market exclusivity for hyaluronidase for injection (Vitrase) to 5 years from 3 years. The exclusivity will end May 5, 2009.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Physician perspective: Glaucoma eye drops are here to stay
2
Commercial red light devices for myopia may exceed safety limits
3
No significant visual gains seen with PDE6A gene supplementation in early-phase trial
4
SparingVision completes PRODYGY trial patient dosing with SPVN06
5
























